NCT01719835 - CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

August 31, 2022

Conditions

Peripheral T-cell Lymphoma NOSAnaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell LymphomaHepatosplenic Gamma/ Delta T-cell LymphomaEnteropathy-Associated T-Cell Lymphoma

Interventions

DRUG

Cyclophosphamide

750mg/m2 IV every 21 days

DRUG

Gemcitabine

1000mg/m2 IV Days 1, 8, 15 every 28 days

DRUG

Doxorubicin

50mg/m2 IV every 21 days

DRUG

Vincristine

1.4mg/m2 (max 2mg) IV every 21 days

DRUG

Prednisolone

100mg PO Days 1-5 every 21 days

DRUG

methylprednisolone

1000mg oral or IV Days 1-5 every 28 days

DRUG

Cisplatin

100mg/m2 IV Day 15 every 28 days

Trial Locations (1)

SM2 5PT

Royal Marsden NHS Foundation Trust - London and Surrey, London